arrow
J

Jeffrey T. Yap

Department of Radiology and Imaging Sciences
H指数:35
被引数:6,770

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT

侵袭性小叶癌的分期:一项关于18F-Fluoroestradiol (FES)-PET/CT有效性的前瞻性研究

2025-11-080
PRE
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers (vol 25, pg 620, 2019)

RAF→MEK→ERK抑制所诱发的保护性自噬表明了一种针对RAS驱动型癌症的治疗策略(卷25,页620,2019)

2025-04-250
PRE
Examination of systemic myokine concentrations with risk of cachexia in non-metastatic colorectal cancer patients - Results from the ColoCare Study
2023-04-040
PRE
Protective autophagy elicited by RAF®MEK®ERK inhibition suggests a treatment strategy for pancreatic cancer
2019-07-010
PRE
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers (vol 25, pg 620, 2019)
2019-03-2719
OAAI
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

Raf → mek → erk抑制引起的保护性自噬提示RAS驱动的癌症的治疗策略

2019-03-04500
OAAI
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

regorafenib在标准酪氨酸激酶抑制剂治疗失败后转移性和/或不可切除的胃肠道间质瘤患者中的多中心II期试验的长期随访结果

2016-09-0188
OAAI
ACRIN 6665/RTOG 0132 Phase II Trial of Neoadjuvant Imatinib Mesylate for Operable Malignant Gastrointestinal Stromal Tumor: Monitoring with 18F-FDG PET and Correlation with Genotype and GLUT4 Expression
2012-03-0146
OAAI